Difelikefalin

(Korsuva®)

Difelikefalin

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 50 mcg/mL)
Drug ClassKappa opioid receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).

Product Monograph / Prescribing Information

Document TitleYearSource
Korsuva (difelikefalin) Prescribing Information.2021Vifor (International) Inc., St. Gallen, Switzerland

Systematic Reviews / Meta-Analyses